secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2023-07-31T23:59:59+00:00
Accession:  0001935979-23-000049
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biohaven Q2 net loss $90.3M; cash $349M; FDA refuses SCA3 NDA; pipeline advances
--------------------------------------------------------------------------------

- Net loss $90.3M ($1.32/sh) vs $203.3M ($5.16/sh) in Q2 2022; adjusted net loss $85.7M ($1.25/sh).
- Cash and marketable securities $349.0M as of June 30, 2023, down from $467.9M at Dec 31, 2022.
- BHV-7000 Kv7 activator showed CNS target engagement without somnolence; Phase 2/3 in epilepsy and bipolar disorder planned 2H 2023.
- FDA refused to file troriluzole NDA for SCA3; Biohaven plans Type A meeting to address FDA concerns.
- BHV-8000 (TYK2/JAK1) Phase 1 SAD dosed, well tolerated; Phase 2 in Parkinson's disease planned 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597923000049/0001935979-23-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597923000049/bhvn-20230731.htm
  HTML page:      https://secwatch.observer/filing/0001935979-23-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer